Zymeworks Q1 2026 Earnings Report Highlights Regulatory Catalysts and Financial Performance
Zymeworks reported first-quarter earnings for fiscal year 2026 with a net loss of $44.2 million, driven by lower milestone revenue compared to the prior-year period. The company highlighted near-term regulatory catalysts including an August 25 PDUFA date in the U.S. and potential approvals in China for its drug candidate Zanidatumab.
Tickers: $JAZZ